Honma M, Ikebuchi Y, Suzuki H. RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target. Pharmacol Ther. 2021;218:107682.
Zartab, Hamed., Maghsoodloo, Dorian., Parsi-Moud, Abolfazl., Ahmadi, Mohammad Amin., & Rezaei Zadeh Rukerd, Mohammad.. (2025). The RANK-RANKL-OPG axis in dermatological malignancies: A systematic review. International immunopharmacology.
Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39(1):19-26.
Santamaria JC, Chevallier J, Dutour L, et al. RANKL treatment restores thymic function and improves T cell-mediated immune responses in aged mice. Sci Transl Med. 2024;16(776):eadp3171.
Frattini, Annalisa., Vezzoni, Paolo., Villa, Anna., & Sobacchi, Cristina.. (2007). The Dissection of Human Autosomal Recessive Osteopetrosis Identifies an Osteoclast-Poor Form due to RANKL Deficiency. Cell cycle (Georgetown, Tex.), 6(24), 3027-3033.
Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18(7):415-429.
Tenshin, Hirofumi., Delgado-Calle, Jesus., Windle, Jolene J., Roodman, G David., & Chirgwin, John M.. (2024). Osteocytes and Paget's Disease of Bone. Current osteoporosis reports.
Zhang Y, Liang J, Liu P, Wang Q, Liu L, Zhao H. The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. Front Endocrinol (Lausanne). 2022;13:1063815.